Navigation Links
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
Date:12/10/2010

tatements about the advancement, therapeutic indication and use, safety, efficacy, tolerability, and mechanism of action of APD811; the potential of APD811 and orally bioavailable prostacyclin receptor agonists in general, including with regard to improving treatment; the protocol, design, scope, enrollment, potential results and other aspects of the Phase 1 clinical trial for APD811; Arena's earlier-stage compounds and related value and potential; Arena's focus on the approval of lorcaserin; the potential therapeutic indication and use, FDA approval and commercialization of lorcaserin; the Eisai collaboration and potential activities thereunder; and Arena's aim, focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: there was a small safety margin from the no observed adverse effect level to significant adverse events in preclinical studies of APD811, and APD811 could have an unacceptable safety and efficacy profile in humans; the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies meet safety or efficacy requirements or are otherwise sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted in a timely manner or the information provided in such response may not satisfy the FDA; the FDA may request additional information prior to approval of the lorcaserin NDA; unexpected new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timi
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
2. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
3. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
4. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
5. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
6. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
7. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
8. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
9. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
11. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 Microbrush International, a leading developer, producer ... restorative procedures, today announced the acquisition of DentiSmart ... sectional matrix system used in dental restorative procedures. ... opportunity to add DentiSmart to our growing portfolio ... VP and General Manager of Microbrush. "DentiSmart,s products ...
(Date:5/4/2015)... May 4, 2015 DePuy Synthes CMF* today ... the first commercially available biosynthesized dural replacement derived from ... a part of the DePuy Synthes Companies of Johnson ... membrane that covers and protects the brain and spinal ... allow surgeons to access the brain. A dural graft, ...
(Date:5/4/2015)... Former NASA scientist Tamim Hamid ... he discussed Theradome™, the first portable and wearable OTC ... shows firsthand how, via laser technology, Theradome™ offers individuals ... will not require surgery or medication.  ... of the hair follicle, which is where the stem ...
Breaking Medicine Technology:Microbrush International Announces Acquisition of DentiSmart 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2
(Date:5/4/2015)... “ LiveSchool ” was featured on ... a look at the latest and coolest applications on ... the host of AppWatch and technology expert, conducted the ... allows teachers to reward students with good behavior. , ... in the classroom. And the good people at ...
(Date:5/4/2015)... The opportunity for children to dream of ... motivating forces behind The Fairy Godmother Next Door, a new ... L. Stark. , The inspiration for the enchanting story of ... from Stark’s desire to be a fairy godmother. , “My ... to my neighbors’ children since they were born. We discuss ...
(Date:5/4/2015)... The U.S. healthcare worker shortage crisis is expected ... senior citizens (1) and 27 million Obamacare-insured Americans (2) ... Additionally, as older healthcare employees retire, there will be ... Census Bureau, the number of American workers 65 and ... those 25 to 54 will likely increase 2%. (3) ...
(Date:5/4/2015)... City, OK and Seattle, WA (PRWEB) May 04, 2015 ... announced the formation of a collaboration to facilitate development ... number of ophthalmic disorders that lead to blindness, including ... to the MiDROPS™ formulation platform developed by EyeCRO, which ... the eye via a topical eyedrop. , Under ...
(Date:5/4/2015)... New findings released today from a poll conducted ... people diagnosed with a brain tumor needed more information ... at the time of diagnosis, and had only a ... course of treatment. The release of these findings corresponds ... volunteer network, the ABTA CommYOUnity™, dedicated to serving the ...
Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3
... , FRIDAY, March 2 (HealthDay News) -- Preemies face a ... British research suggests that the degree to which a child,s ... the child was. Those born between the 32nd and ... health issues than those born slightly later in the 37th ...
... , FRIDAY, March 2 (HealthDay News) -- When ... very premature deliveries, obstetricians are strongly influenced by parents, ... to save their baby,s life, a new study finds. ... 22 weeks and 26 weeks gestation (also known as ...
... A scientific method paper and video by Loyola researchers ... technique used to study some aspects of mitochondrial dysfunctions ... It has been accessed by more than 14,000 scientists ... Journal of Visualized Experiments , a peer-reviewed, PubMed-indexed ...
... FRIDAY, March 2 (HealthDay News) -- Women become less likely ... first year of college, new research finds. Declining condom ... had worse grades and who came from poorer backgrounds. ... unplanned pregnancies and sexually transmitted diseases, yet there has been ...
... HealthDay Reporter , FRIDAY, March 2 (HealthDay News) ... high blood pressure, diabetes and other chronic conditions can have ... choices exist for some types of drugs, adjusting medications is ... pharmacy officer with the Harris County Hospital District, in Houston. ...
... FRIDAY, March 2 (HealthDay News) -- The social networking ... platform for derogatory comments about epilepsy and seizures, researchers ... issue of Epilepsy and Behavior , Canadian researchers ... of them as offensive. The study authors pointed out ...
Cached Medicine News:Health News:Timing of Preemie Birth May Be Key to Kids' Health Later 2Health News:Parents' Wishes Sway Docs' Choices on Preterm Deliveries 2Health News:Video publication goes viral 2Health News:College Women's Condom Use Falls in Freshman Year 2Health News:Prescription Meds Can Put on Unwanted Pounds 2Health News:Prescription Meds Can Put on Unwanted Pounds 3Health News:Twitter Adding to Stigma of Epilepsy, Study Says 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: